While the US Food and Drug Administrative has long emphasized the desire for more innovative trial designs, Amgen Inc. offered the agency specific advice on how it could promote their adoption.
Elliott Levy, Amgen's senior VP of global development, recommended that FDA hold informal communications with sponsors, in which there is "more asking and less talking
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?